文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

纤维细胞驱动JAK2V617F突变骨髓纤维化:匹伐他汀逆转骨髓纤维化与贫血

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.
PubMed 文献 · Blood · 2026-01-01

该研究揭示纤维细胞是JAK2V617F突变骨髓纤维化患者骨髓中主要产胶原细胞,占近三分之二。高通量药物筛选发现他汀类抑制纤维细胞增殖,匹伐他汀在Jak2V617F小鼠中减少纤维细胞、改善骨髓纤维化和贫血,并降低TGF-β1产生。患者外周血纤维细胞体外同样对匹伐他汀敏感。

要点

  • 纤维细胞是JAK2V617F突变骨髓纤维化骨髓中主要产胶原细胞,占比近三分之二。
  • 匹伐他汀在Jak2V617F小鼠中减少纤维细胞、改善骨髓纤维化和贫血。
  • 匹伐他汀降低肿瘤性纤维细胞TGF-β1产生,减少肌纤维母细胞扩增。

核心结论

  • 纤维细胞显著贡献于JAK2V617F突变骨髓纤维化的骨髓纤维化,支持进一步研究匹伐他汀作为该分子亚型的潜在抗纤维化策略。

研究设计与样本

  • 分析JAK2V617F突变骨髓增殖性肿瘤患者骨髓样本中产胶原细胞组成。
  • 利用Jak2V617F转基因小鼠骨髓来源纤维细胞进行高通量药物筛选。
  • 在Jak2V617F小鼠体内评估匹伐他汀疗效,并体外测试患者外周血纤维细胞敏感性。

主要发现

  • JAK2V617F突变骨髓纤维化患者骨髓中纤维细胞占产胶原细胞近三分之二,肌纤维母细胞为较小亚群。
  • 高通量筛选鉴定他汀类为纤维细胞增殖体外抑制剂。
  • 匹伐他汀体内减少Jak2V617F小鼠纤维细胞数量、改善骨髓纤维化和贫血。
  • 匹伐他汀降低肿瘤性纤维细胞TGF-β1产生,减少肌纤维母细胞扩增。
  • JAK2V617F突变骨髓增殖性肿瘤患者外周血来源纤维细胞体外对匹伐他汀敏感。

临床怎么用

  • 提示纤维细胞可作为JAK2V617F突变骨髓纤维化的潜在治疗靶点。
  • 匹伐他汀可能作为该分子亚型骨髓纤维化的抗纤维化策略,需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bone marrow (BM) fibrosis in primary and post-polycythemia vera/essential thrombocythemia myelofibrosis (MF) has traditionally been considered a reactive process driven by cytokines, such as transforming growth factor β1 (TGF-β1), primarily produced by neoplastic megakaryocytes and platelets. These cytokines promote the differentiation of wild-type mesenchymal stromal cells into collagen- and fibronectin-producing myofibroblasts, thereby inducing BM fibrosis. However, hematopoietic-derived collagen-producing cells of monocyte lineage, termed fibrocytes, have also been implicated in this process. Here, we demonstrate that fibrocytes constitute a major collagen-producing cell population in the BM of patients with JAK2V617F-mutated MF, with additional contributions from myofibroblasts. Analysis of BM samples from patients with JAK2V617F-mutated myeloproliferative neoplasms (MPNs) revealed that fibrocytes accounted for nearly two-thirds of collagen-producing cells, whereas myofibroblasts represented a smaller subset. Using BM-derived fibrocytes from Jak2V617F transgenic mice (Jak2V617F mice), we performed a high-throughput drug screen and identified statins as inhibitors of fibrocyte proliferation in vitro. In vivo, pitavastatin treatment reduced fibrocyte numbers, ameliorated BM fibrosis, and improved anemia in Jak2V617F mice. Pitavastatin also decreased TGF-β1 production by neoplastic fibrocytes, resulting in reduced myofibroblast expansion. Peripheral blood-derived fibrocytes from patients with JAK2V617F-mutated MPNs were similarly sensitive to pitavastatin in vitro. Together, these findings suggest that fibrocytes substantially contribute to BM fibrosis in JAK2V617F-mutated MF and support further investigation of pitavastatin as a potential antifibrotic strategy in this molecular subset.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Uchida T, Shide K, Kameda T, et al. Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia. Blood. 2026. PMID: 42391645. doi:10.1182/blood.2025032693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。